As FDA Review Looms, Drug Cos. Defend Vytorin Study
Merck & Co. and Schering-Plough Corp. continued to defend a controversial study of their Vytorin and Zetia cholesterol treatments Friday on the heels of the U.S. Food and Drug Administration announcing...To view the full article, register now.
Already a subscriber? Click here to view full article